Moleculin preclin data: Annamycin shows efficacy in liver cancers; AML readout H2 2025

Moleculin Biotech, Inc.

Annamycin demonstrated anti-tumor activity in orthotopic HCC models, colorectal liver metastases, and PDAC liver metastases.
Preclinical data show targeted organ accumulation (liver, spleen, lungs, pancreas) vs doxorubicin; no cardiotoxicity seen.
Prior clinical data: 32 of 42 subjects received >FDA lifetime max anthracycline without cardiotoxicity.
Preliminary data readout for Annamycin in AML expected in second half of 2025.
Data presented at Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.